Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol/Otsuka’s Abilify New Rx Share Exceeds 10%

This article was originally published in The Pink Sheet Daily

Executive Summary

Total scripts for the atypical antipsychotic were 700,000 in the fourth quarter, up more than 10% sequentially. Abilify has received additional sales support from Bristol despite the company’s reduction in the overall size of its detail team.

You may also be interested in...



Bristol/Otsuka's Abilify Adds Oral Solution Formulation

The atypical antipsychotic's new formulation will be available in February, the companies say. Abilify is the second drug in the class available as an oral solution, after J&J's Risperdal. Supplemental NDAs for additional Abilify formulations are pending at FDA, Bristol says.

Bristol/Otsuka's Abilify Adds Acute Bipolar Mania Indication

FDA clears aripiprazole for the treatment of acute manic and mixed episodes associated with bipolar disorder. The approval places Abilify labeling on par with other atypical antipsychotics.

US FDA Expands Drug Development Tool Qualification Program With ISTAND Pilot

ClinROs, artificial intelligence-based algorithms will be included in approval pathway. FDA is taking a crash course on new techniques for trial assessment thanks to COVID.

Topics

UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel